Ask AI
ProCE Banner Activity

ClinicalThought Expert Office Hours Forum: Implementing Systemic Therapy in H3K27-Altered DMG 

Clinical Thought

A recent FDA approval of a drug indicated for patients with diffuse midline glioma (DMG) with a mutation in H3K27 has led to an overhaul of how this cancer is treated in pediatric and adult patients. In this clinical forum, experts will answer questions related to the program, “Implementing Systemic Therapy in H3K27-Altered DMG: Practical Strategies to Optimize Postradiation Care.” This social media forum provides learners with ongoing access to faculty throughout the certified life of this program. Learners are encouraged to submit their questions here.

Released: August 24, 2026

Review Activity

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education.

ProCE Banner

Supporters

This activity is supported by an educational grant from Jazz Pharmaceuticals, Inc.

Jazz Pharmaceuticals, Inc.

Target Audience

This program is intended for neuro-oncologists and other healthcare professionals who care for patients with diffuse midline glioma. 

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Apply molecular testing pathways to confirm H3 K27 status and document eligibility decisions at diagnosis and progression

  • Interpret the latest efficacy, safety, and regulatory data supporting protease activator therapy in recurrent DMG following radiation to inform evidence-based care decisions

  • Implement a post-RT sequencing algorithm integrating symptoms, steroid trajectory, imaging interpretation, and trial referral ready monitoring workflow (QTc risk screening/monitoring, symptom triage, escalation thresholds) in pediatric and adult settings

  • Identify patients for biomarker-driven clinical trials investigating novel targeted therapies and combination strategies in DMG, including earlier-line settings where clinically appropriate

Financial Disclosures

Primary Author

Stephen J. Bagley, MD, MSCE: researcher (paid to institution): Incyte, Kite; advisor: Jazz, Servier.

Carl Koschmann, MD: researcher (paid to institution): Jazz

Karen D. Wright, MD, MS: patent (pending): Day One Biopharmaceuticals.